Lixisenatide in type 2 diabetes and acute coronary syndrome: To the editor

New England Journal of Medicine

Volumn 374, Issue 11, 2016, Pages 1095-

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; GLYCOSYLATED HEMOGLOBIN; LIXISENATIDE; PLACEBO; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; PIPERIDINE DERIVATIVE; URACIL;

ACUTE CORONARY SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; AGONISTS; ANALOGS AND DERIVATIVES; ANGINA, UNSTABLE; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; PEPTIDES; PIPERIDINES; URACIL;

EID: 84961828437     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1600140     Document Type: Letter

References (2)

1. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35.
2. Derosa G, Maffioli P. EXAMINE: targeting risk and treatment in diabetes. Lancet 2015; 386: 1443.